Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Humana Inc. (NYSE:HUM). In a filing disclosed on June 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Humana stock on May 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
- Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
- Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
- Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
- Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
- Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
- Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
- Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.
Humana Stock Up 2.5%
NYSE HUM traded up $5.80 during trading on Wednesday, reaching $236.92. 1,913,795 shares of the company's stock were exchanged, compared to its average volume of 1,830,240. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $406.09. The company's fifty day simple moving average is $234.87 and its 200-day simple moving average is $257.29. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $28.59 billion, a PE ratio of 16.76, a P/E/G ratio of 1.53 and a beta of 0.44.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same quarter in the previous year, the firm earned $7.23 EPS. Humana's quarterly revenue was up 8.4% on a year-over-year basis. Sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current year.
Institutional Investors Weigh In On Humana
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in shares of Humana during the second quarter worth $218,000. KLP Kapitalforvaltning AS increased its stake in Humana by 6.5% during the second quarter. KLP Kapitalforvaltning AS now owns 44,370 shares of the insurance provider's stock valued at $10,881,000 after purchasing an additional 2,700 shares during the last quarter. Prime Capital Investment Advisors LLC grew its position in shares of Humana by 10.6% during the second quarter. Prime Capital Investment Advisors LLC now owns 953 shares of the insurance provider's stock worth $233,000 after acquiring an additional 91 shares during the last quarter. Sendero Wealth Management LLC grew its position in shares of Humana by 28.2% during the second quarter. Sendero Wealth Management LLC now owns 4,440 shares of the insurance provider's stock worth $1,085,000 after acquiring an additional 978 shares during the last quarter. Finally, Willner & Heller LLC grew its position in Humana by 23.5% in the 2nd quarter. Willner & Heller LLC now owns 2,180 shares of the insurance provider's stock valued at $533,000 after buying an additional 415 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages recently issued reports on HUM. Robert W. Baird increased their price target on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Barclays set a $268.00 target price on Humana and gave the stock an "equal weight" rating in a research report on Thursday, June 12th. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research note on Thursday, May 1st. Finally, Bank of America cut their target price on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Sixteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $282.57.
View Our Latest Research Report on HUM
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Humana
(
Get Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
